CELC241220C22500
- 0.60
- 0.000.00%
Celcuity Newsroom
Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (HIMS) and Celcuity (CELC)
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $27 to $42
Celcuity Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Stifel Nicolaus Remains a Buy on Celcuity (CELC)
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $23 to $27
Celcuity's Strong Financial Position and Promising Drug Pipeline Support Buy Rating Despite Trial Delays
Celcuity Analyst Ratings
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating
Celcuity (CELC) Gets a Buy From Craig-Hallum
Celcuity Is Maintained at Buy by Stifel
Celcuity Analyst Ratings
Stifel Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $42
LifeSci Capital Initiates Coverage on Celcuity With Outperform Rating, $27 Price Target
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $23 to $39
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $23 to $39
Celcuity Analyst Ratings
Analysts Conflicted on These Healthcare Names: Verrica Pharmaceuticals (VRCA), Celcuity (CELC) and Bluebird Bio (BLUE)
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating